These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 9665008)

  • 1. Does tacrolimus cause more severe anemia than cyclosporine A in children after renal transplantation?
    Peter C; Latta K; Graf D; Offner G; Brodehl J
    Transpl Int; 1998; 11 Suppl 1():S328-30. PubMed ID: 9665008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria.
    Morrissey PE; Gohh R; Shaffer D; Crosson A; Madras PN; Sahyoun AI; Monaco AP
    Transplantation; 1997 Mar; 63(6):845-8. PubMed ID: 9089224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
    Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential cardiovascular risk factors in paediatric renal transplant recipients.
    Ferraris JR; Ghezzi L; Waisman G; Krmar RT
    Pediatr Nephrol; 2006 Jan; 21(1):119-25. PubMed ID: 16252106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation.
    Johnson C; Ahsan N; Gonwa T; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; van Veldhuisen P; Salm K; Tolzman D; Fitzsimmons WE
    Transplantation; 2000 Mar; 69(5):834-41. PubMed ID: 10755536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching from cyclosporine to tacrolimus in patients with chronic transplant dysfunction or cyclosporine-induced adverse events.
    Cantarovich D; Renou M; Megnigbeto A; Giral-Classe M; Hourmant M; Dantal J; Blancho G; Karam G; Soulillou JP
    Transplantation; 2005 Jan; 79(1):72-8. PubMed ID: 15714172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular risk profile after conversion from cyclosporine A to tacrolimus in stable renal transplant recipients.
    Baid-Agrawal S; Delmonico FL; Tolkoff-Rubin NE; Farrell M; Williams WW; Shih V; Auchincloss H; Cosimi AB; Pascual M
    Transplantation; 2004 Apr; 77(8):1199-202. PubMed ID: 15114085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Smooth muscle-specific actin levels in the urine of renal transplant recipients: correlation with cyclosporine or tacrolimus nephrotoxicity.
    Haas M; Meehan SM; Josephson MA; Wit EJ; Woodle ES; Thistlethwaite JR
    Am J Kidney Dis; 1999 Jul; 34(1):69-84. PubMed ID: 10401019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse Events under Tacrolimus and Cyclosporine in the First 3 Years Post-Renal Transplantation in Children.
    Lancia P; Aurich B; Ha P; Maisin A; Baudouin V; Jacqz-Aigrain E
    Clin Drug Investig; 2018 Feb; 38(2):157-171. PubMed ID: 29236209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression.
    Hernández D; Miquel R; Porrini E; Fernández A; González-Posada JM; Hortal L; Checa MD; Rodríguez A; García JJ; Rufino M; Torres A
    Transplantation; 2007 Sep; 84(6):706-14. PubMed ID: 17893603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late, severe, noninfectious diarrhea after renal transplantation: high-risk factors, therapy, and prognosis.
    Zhao YJ; Wen JQ; Cheng K; Ming YZ; She XG; Liu H; Liu L; Ye QF; Ding BN
    Transplant Proc; 2013; 45(6):2226-32. PubMed ID: 23953533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence, severity, and risk variables associated with gingival overgrowth in renal transplant subjects treated under tacrolimus or cyclosporin regimens.
    de Oliveira Costa F; Diniz Ferreira S; de Miranda Cota LO; da Costa JE; Aguiar MA
    J Periodontol; 2006 Jun; 77(6):969-75. PubMed ID: 16734570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation.
    Porayko MK; Textor SC; Krom RA; Hay JE; Gores GJ; Richards TM; Crotty PH; Beaver SJ; Steers JL; Wiesner RH
    Mayo Clin Proc; 1994 Feb; 69(2):105-11. PubMed ID: 7508536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency of hyperuricemia and effect of calcineurin inhibitors on serum uric acid levels in liver transplanted children.
    Tumgor G; Arikan C; Kilic M; Aydogdu S
    Pediatr Transplant; 2006 Sep; 10(6):665-8. PubMed ID: 16911488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New onset dyslipidemia after renal transplantation: is there a difference between tacrolimus and cyclosporine?
    Deleuze S; Garrigue V; Delmas S; Chong G; Swarcz I; Cristol JP; Mourad G
    Transplant Proc; 2006 Sep; 38(7):2311-3. PubMed ID: 16980075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
    Levy G; Grazi GL; Sanjuan F; Wu Y; Mühlbacher F; Samuel D; Friman S; Jones R; Cantisani G; Villamil F; Cillo U; Clavien PA; Klintmalm G; Otto G; Pollard S; McCormick PA
    Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclosporine-associated thrombotic microangiopathy/hemolytic uremic syndrome following kidney and kidney-pancreas transplantation.
    Young BA; Marsh CL; Alpers CE; Davis CL
    Am J Kidney Dis; 1996 Oct; 28(4):561-71. PubMed ID: 8840947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation.
    Vacher-Coponat H; Moal V; Indreies M; Purgus R; Loundou A; Burtey S; Brunet P; Moussi-Frances J; Daniel L; Dussol B; Berland Y
    Transplantation; 2012 Feb; 93(4):437-43. PubMed ID: 22228415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.